No connection

Search Results

AVNS vs SIBN

AVNS
Avanos Medical, Inc.
BEARISH
Price
$13.09
Market Cap
$607.6M
Sector
Healthcare
AI Confidence
68%
SIBN
SI-BONE, Inc.
NEUTRAL
Price
$14.09
Market Cap
$622.3M
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
AVNS
--
SIBN
--
Forward P/E
AVNS
13.78
SIBN
-36.94
P/B Ratio
AVNS
0.78
SIBN
3.46
P/S Ratio
AVNS
0.87
SIBN
3.1
EV/EBITDA
AVNS
9.0
SIBN
-30.87

Profitability

Gross Margin
AVNS
52.28%
SIBN
79.57%
Operating Margin
AVNS
0.28%
SIBN
-4.37%
Profit Margin
AVNS
-67.0%
SIBN
-9.41%
ROE
AVNS
-46.68%
SIBN
-10.97%
ROA
AVNS
1.58%
SIBN
-5.95%

Growth

Revenue Growth
AVNS
4.3%
SIBN
15.0%
Earnings Growth
AVNS
--
SIBN
--

Financial Health

Debt/Equity
AVNS
0.17
SIBN
0.21
Current Ratio
AVNS
2.38
SIBN
8.55
Quick Ratio
AVNS
1.23
SIBN
7.05

Dividends

Dividend Yield
AVNS
--
SIBN
--
Payout Ratio
AVNS
0.0%
SIBN
0.0%

AI Verdict

AVNS BEARISH

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant operational and profitability concerns. Despite a low Price/Book and Price/Sales ratio suggesting potential value, the company is unprofitable with a -67% profit margin and negative ROE of -46.68%, undermining valuation appeal. While revenue growth is positive at 4.3% YoY and recent earnings surprises have been strong, the lack of sustained profitability, deteriorating insider sentiment, and poor long-term price performance (-72.6% over 5 years) raise serious concerns. The absence of Altman Z-Score and key financial data limits confidence, but current signals point to a distressed or speculative investment.

Strengths
Revenue growth of 4.3% YoY shows top-line resilience in a challenging sector environment
Gross margin of 52.28% indicates strong pricing power and cost control at the production level
Low valuation multiples: P/B of 0.78 and P/S of 0.87 suggest potential undervaluation relative to book and sales
Risks
Piotroski F-Score of 2/9 signals severe financial weakness, particularly in profitability and leverage metrics
Profit margin of -67% and ROE of -46.68% indicate deep unprofitability and inefficient use of equity
Missing Altman Z-Score prevents definitive distress assessment, but negative earnings and ROE imply high bankruptcy risk
SIBN NEUTRAL

SIBN presents a classic high-risk, high-reward growth profile, characterized by a stable Piotroski F-Score of 4/9 and exceptional liquidity. While the company remains unprofitable with negative net margins, it demonstrates a strong trajectory of narrowing losses and consistent earnings beats (average surprise 40.87%). The balance sheet is fortress-like with a current ratio of 8.55 and low debt, but this is offset by heavy insider selling and a long-term bearish price trend. The disconnect between the 'Strong Buy' analyst consensus and the bearish insider sentiment suggests a speculative environment.

Strengths
Exceptional liquidity with a Current Ratio of 8.55 and Quick Ratio of 7.05
Very strong Gross Margin of 79.57%, indicating high product value and pricing power
Consistent track record of beating earnings estimates (3 of last 4 quarters)
Risks
Negative Profit Margin (-9.41%) and Operating Margin (-4.37%)
Heavy insider selling (15 sell transactions, 0 buys) totaling $4.37M
Long-term price erosion with a 5-year change of -59.4%

Compare Another Pair

AVNS vs SIBN: Head-to-Head Comparison

This page compares Avanos Medical, Inc. (AVNS) and SI-BONE, Inc. (SIBN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile